Figure 1.

Differential Expression of lncRNAs Induced by Cisplatin in TSCC Cells and Chemosensitive or Chemoresistant Tumors

(A) Scatterplot showing variation in lncRNA expression between treated and non-treated TSCC cells. The values on the X- and Yaxes are the average normalized signal values of the group (log2 scaled). The green and red dots represent fold change ≥2.0.

(B) Heatmap showing 38 upregulated lncRNAs in both treated TSCC cell lines compared with the untreated cells. The relative lncRNA expression is depicted according to the color scale. Venn diagram of the intersection of the upregulated lncRNAs in both treated TSCC cell lines versus the untreated cells. Thirty-eight lncRNAs showed a fold change ≥4.0.

(C) Thirteen lncRNAs were identified to be significantly upregulated in TSCC tumors with chemosensitive (PS) and chemoresistant tumors (PNS).

(D) Schematic annotation of the CISAL genomic locus on chr6:2,988,648-2,991,173 in humans. Green rectangles represent exons.

(E) Representative MRI scans of tumor response (upper panels) and CISAL expression (lower panels) in tissue specimens from patient with chemosensitive and chemoresistant TSCC tumors.

(F) CISAL expression in each patient was analyzed by in situ hybridization; 5×200 tumor cells were randomly counted in each tumor.

*p<0.05, **p<0.01, and ***p<0.001 versus control, (C) 2-tailed Student's t test; (F) 1-way ANOVA followed by Dunnett's tests for multiple comparisons.